Clinical development readiness in Nigeria and West Africa requires more than a compliant protocol or a promising scientific concept. It requires a detailed understanding of the clinical development lifecycle and a practical plan for how the study will perform under local conditions.
Clinical development lifecycle
The lifecycle begins with early-phase planning and extends through pivotal studies, regulatory submissions, approval, and post-approval surveillance. Each stage requires a different combination of feasibility assessment, clinical operations capability, regulatory engagement, and safety monitoring.
For example, early phase activities focus on protocol feasibility and site selection, while later stage programs require more sophisticated risk management, data strategy, and regulatory alignment.
Nigerian regulatory considerations
Nigerian regulatory readiness includes understanding NAFDAC requirements, ethics committee timelines, import permit processes, and the expectations for local safety reporting. Sponsors should also evaluate whether the planned investigational product is subject to specific local regulations, labelling guidelines, or importation controls.
MedNova supports sponsor teams by clarifying when to engage the local regulator, what documentation is required, and how to coordinate submission packages with the operational timeline.
Sponsor readiness
Sponsor readiness means assessing governance, vendor oversight, quality systems, and resourcing before the first site initiation. A ready sponsor can articulate the roles of the global team, local study managers, medical monitors, and pharmacovigilance partners.
It also means confirming that the sponsor has a clear escalation path for risk decisions, a process for protocol amendments, and a defined approach for managing data and safety signals as the study progresses.
CRO preparation
CRO readiness is not limited to selecting a qualified vendor. It includes making sure the CRO has the local knowledge, logistical support, and regulatory experience needed for the selected sites. This may involve training investigators, establishing supply chain arrangements, and confirming that the CRO understands the local clinical trial ecosystem.
Effective CRO preparation also includes testing the handover of critical documents, clarifying roles for monitoring and data management, and ensuring the CRO can manage local challenges such as site staffing shortages or complex import procedures.
Common mistakes
- Assuming that global clinical development plans translate directly to local markets without a tailored feasibility review.
- Underestimating the time required for ethics review, customs clearance, and NAFDAC approvals.
- Separating regulatory and operational readiness instead of coordinating them from the outset.
- Failing to build a clear oversight model for pharmacovigilance, regulatory affairs, and quality functions in the same program.
How professionals can use this guidance
Clinical development teams use this readiness guidance as a practical planning tool. It helps them identify gaps in protocol execution, understand the interplay between regulatory requirements and site operations, and incorporate local risk factors into the overall study strategy.
It is also useful for CRO teams and sponsors who are preparing to work together for the first time in Nigeria or West Africa.
FAQs
What should sponsors review first?
The first review should focus on feasibility, local regulatory expectations, and the adequacy of site resources. This includes checking whether the proposed population is accessible, whether the sites can manage the investigational product, and whether the local approvals timeline supports the planned start date.
How does NAFDAC affect clinical timelines?
NAFDAC and ethics committee timelines can be a critical path item. Early engagement with regulators and a realistic submission plan help reduce surprises and support a smoother pathway to site activation.
When should a CRO be engaged?
A CRO should be engaged early enough to contribute to feasibility, local regulatory planning, site selection, and startup logistics. That ensures the CRO’s operational model is aligned with the study design and local requirements.
MedNova’s practical approach
MedNova works with sponsors and CROs to bridge strategic planning, regulatory readiness, and operational delivery. We help teams move from high-level timelines to a practical execution plan that includes compliance, quality, and local delivery considerations.
If you want a deeper review of your clinical development readiness, contact MedNova Lifesciences to discuss your next programme and the support that can improve execution in West Africa.